Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 2.
doi: 10.1007/s40618-025-02639-9. Online ahead of print.

Global epidemiology of pheochromocytoma: a systematic review and meta-analysis of observational studies

Giacomo Vitturi #  1 , Salvatore Crisafulli #  1 , Ylenia Alessi  2   3   4 , Sara Frontalini  1 , Marilisa Giustina Stano  1 , Andrea Fontana  5 , Giuseppe Giuffrida  6 , Francesco Ferraù  7   8 , Gianluca Trifirò  1 , Salvatore Cannavò  4   9
Affiliations
Review

Global epidemiology of pheochromocytoma: a systematic review and meta-analysis of observational studies

Giacomo Vitturi et al. J Endocrinol Invest. .

Abstract

Objective: The aim of this systematic review and meta-analysis of observational studies is to provide an overview of the global epidemiology of pheochromocytomas and to evaluate the quality of study reporting for the identified studies.

Methods: Two bibliographic databases, PubMed and Embase, were searched for studies assessing the epidemiology of pheochromocytoma from inception until December 2024. Original observational studies written in English and reporting pheochromocytoma prevalence and/or incidence for a well-defined geographic area were included. Two reviewers independently screened the retrieved articles for inclusion, extracted relevant data, and carried out the evaluation of the quality of study reporting. A narrative synthesis of the results was provided, along with a meta-analysis of both prevalence and incidence of pheochromocytoma.

Results: A total of 14 studies were included in the systematic review, of which 13 were included in the meta-analysis. The pooled prevalence of pheochromocytoma was 19.8 (95% CI: 9.6-40.8) cases per 1,000,000 individuals, and the incidence rate was 1.9 (95% CI: 1.2-2.6) cases per million person-years. Substantial between-study heterogeneity was observed for both prevalence and incidence rates (I2 = 98.7 for both), mainly due to different geographic areas and the use of different data sources. The quality of study reporting was rated as high for only one study, low for four studies, and medium for the remaining nine.

Conclusions: Overall, our systematic review and meta-analysis of observational studies revealed significant between-study heterogeneity of prevalence of pheochromocytoma amounting to around 20 per million individuals. Establishing national registries using standardized diagnostic and clinical parameters, along with well-defined selection and analysis criteria, may provide better insight into the epidemiology and the course of this rare disease.

Keywords: Epidemiology; Meta-analysis; Pheochromocytoma; Systematic review.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: Gianluca Trifirò has served, over the last 3 years, on advisory boards/seminars funded by Sanofi, MSD, Eli Lilly, Sobi, Celgene, Daichii Sankyo, Novo Nordisk, Gilead, and Amgen on topics not related to content of this paper; he is also a scientific coordinator of the academic spin-off “INSPIRE srl,” which has received funding from several pharmaceutical companies (Kiowa Kirin, Shonogi, Shire, Novo Nordisk, and Daichii Sankyo) for conducting observational studies and additional consultancy services on topics not related to the content of this paper. Additionally, he is currently a consultant for Viatris in a legal case concerning a topic not related to the content of this paper. The other authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Similar articles

See all similar articles

References

    1. Lenders JWM, Duh Q-Y, Eisenhofer G et al (2014) Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99:1915–1942. https://doi.org/10.1210/jc.2014-1498 - DOI - PubMed
    1. Pourian M, Mostafazadeh DB, Soltani A (2015) Does this patient have pheochromocytoma? A systematic review of clinical signs and symptoms. J Diabetes Metab Disord 15:11. https://doi.org/10.1186/s40200-016-0230-1 - DOI - PubMed
    1. Soltani A, Pourian M, Davani BM (2017) Correction to: Does this patient have Pheochromocytoma? a systematic review of clinical signs and symptoms. J Diabetes Metab Disord 16:42. https://doi.org/10.1186/s40200-017-0324-4 - DOI - PubMed - PMC
    1. Adler JT, Meyer-Rochow GY, Chen H et al (2008) Pheochromocytoma: current approaches and future directions. Oncologist 13:779–793. https://doi.org/10.1634/theoncologist.2008-0043 - DOI - PubMed
    1. Garcia-Carbonero R, Matute Teresa F, Mercader-Cidoncha E et al (2021) Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas. Clin Transl Oncol 23:1995–2019. https://doi.org/10.1007/s12094-021-02622-9 - DOI - PubMed - PMC

LinkOut - more resources